Core Insights - The company reported a slight increase in revenue and a significant rise in net profit for the first half of 2025, indicating positive financial performance despite challenges in certain product lines [1][2]. Financial Performance - The company achieved operating revenue of 2.635 billion yuan, a year-on-year increase of 0.11% [2]. - The net profit attributable to shareholders was 303.65 million yuan, reflecting a year-on-year increase of 19.91% [2]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was 237.21 million yuan, showing a year-on-year increase of 32.21% [2]. - Basic and diluted earnings per share were both 0.25 yuan, up from 0.21 yuan in the same period last year [2]. - The weighted average return on equity increased to 3.49% from 2.96% year-on-year [2]. Cash Flow and Assets - The net cash flow from operating activities increased by 98.99% compared to the same period last year, primarily due to a higher increase in cash received from sales compared to cash paid for purchases [3]. - Total assets at the end of the reporting period were 12.674 billion yuan, up from 12.286 billion yuan at the end of the previous year [2]. - The net assets attributable to shareholders increased to 8.771 billion yuan from 8.522 billion yuan year-on-year [2]. Revenue Drivers - The revenue growth was mainly driven by a significant increase in sales of innovative and self-developed drugs, despite a decline in some proprietary products due to terminal demand and centralized procurement policies [2]. - The decrease in government subsidies related to revenue and gains from equity disposals contributed to the higher growth rate of net profit after deducting non-recurring items compared to the overall net profit [3].

Core Viewpoint - Yifan Pharmaceutical (002019) reported a slight revenue growth of 0.11% year-on-year for the first half of 2025, with significant profit growth driven by innovative drug sales [1] Financial Performance - The company achieved a revenue of 2.635 billion yuan in the first half of 2025 [1] - Net profit attributable to shareholders reached 304 million yuan, reflecting a year-on-year increase of 19.91% [1] Business Segments - Sales revenue from innovative drugs surged by 169.57% year-on-year, contributing to a rapid increase in the proportion of high-margin business [1] - The growth in innovative drug sales was identified as the core driver for the substantial improvement in the company's non-recurring profit margin [1]

格隆汇8月14日丨亿帆医药(002019.SZ)公布2025年半年度报告，上半年公司实现营业收入26.35亿元，同 比增长0.11%；归属于上市公司股东的净利润3.04亿元，同比增长19.91%；归属于上市公司股东的扣除 非经常性损益的净利润2.37亿元，同比增长32.21%；基本每股收益0.25元。 ...

Core Points - The document outlines the rules for the Nomination Committee of Yifan Pharmaceutical Co., Ltd., aimed at standardizing the selection of directors and senior management, optimizing the board composition, and improving corporate governance [1][2]. Chapter Summaries Chapter 1: General Provisions - The Nomination Committee is established to draft selection criteria and procedures for directors and senior management, and to review candidates' qualifications [1]. - The committee is a specialized working body set up by the board of directors based on shareholder proposals [1]. Chapter 2: Composition - The committee consists of three directors, with independent directors making up more than half [2]. - The term of the committee aligns with that of the board, and members can be re-elected [2][3]. Chapter 3: Responsibilities and Authority - The main responsibilities include proposing the size and composition of the board, researching selection criteria for directors and senior management, and reviewing candidates [4][5]. - The committee must provide recommendations on the nomination or dismissal of directors and the hiring or firing of senior management [5]. Chapter 4: Meeting Procedures - The committee must hold at least one regular meeting within four months after the end of each fiscal year [6]. - Meetings can be held in person or via video/phone, and must be notified in advance [6][7]. Chapter 5: Voting Procedures - A quorum of two-thirds of the committee members is required for meetings [8]. - Voting is conducted by secret ballot, and decisions require a majority approval from all members [9]. Chapter 6: Miscellaneous - The rules take effect upon approval by the board and replace any previous rules [12]. - The board holds the interpretation rights of these rules [12].

Core Points - The internal control system of Yifan Pharmaceutical Co., Ltd. aims to enhance operational management, risk prevention, and sustainable development while safeguarding the rights of employees and investors [1][2]. Internal Control Management - The company establishes five key elements for effective internal control: internal environment, risk assessment, control activities, information and communication, and internal supervision [2][3]. - Six principles guide the internal control implementation: comprehensiveness, importance, checks and balances, adaptability, cost-effectiveness, and authority [3][4]. Responsibilities and Roles - The board of directors is responsible for the internal control system's formulation and execution, while the audit committee supervises its implementation [11][12]. - The management team, including the president and senior executives, is tasked with daily operations and internal control execution [7][8]. Risk Assessment - The company conducts comprehensive risk assessments to identify internal and external risks, determining risk tolerance levels [29][30]. - Internal risks include factors related to human resources, management, innovation, financial status, and safety [31][32]. Control Activities - Internal control activities encompass all business processes related to financial reporting and information disclosure, employing various control measures [37][38]. - The company implements separation of incompatible duties, authorization controls, accounting system controls, asset protection controls, budget controls, operational analysis controls, and performance evaluation controls [39][40]. Information and Communication - The company establishes a system for collecting, processing, and transmitting internal control-related information to ensure effective communication [47][48]. - Information technology is utilized to enhance information integration and sharing [50]. Internal Supervision - The internal audit department is responsible for evaluating the effectiveness of internal controls and reporting deficiencies to the board and audit committee [53][54]. - The company maintains records of the internal control establishment and implementation process to ensure verifiability [55]. Special Risk Control - The company emphasizes management control over subsidiaries, including establishing control systems and coordinating risk management strategies [57][58].

Core Points - The document outlines the rules governing the board of directors of Yifan Pharmaceutical Co., Ltd, aiming to enhance corporate governance and protect the rights of shareholders [1][2][3] Chapter Summaries Chapter 1: General Principles - The rules are established to standardize the board's behavior, improve governance structure, and ensure efficient decision-making [1] - The board is responsible for executing the resolutions of the shareholders' meeting and must comply with relevant laws and the company's articles of association [1][2] Chapter 2: Powers of the Board - The board consists of 6 directors, including 2 independent directors and 1 employee representative [2] - The board has the authority to convene shareholder meetings, execute resolutions, decide on business plans, and manage financial matters [2][3] Chapter 3: Directors - Directors must be natural persons and cannot hold office under certain disqualifying conditions, such as criminal convictions or bankruptcy [6][7] - Directors have a duty to act in the best interests of the company and avoid conflicts of interest [11] Chapter 4: Board Meetings - Board meetings can be regular or temporary, with at least two meetings held annually [12] - Meetings must be notified to all directors in advance, and a quorum requires the presence of more than half of the directors [14] Chapter 5: Voting and Resolutions - Resolutions require a majority vote from all directors present, and directors with conflicts of interest must abstain from voting [24][25] - The results of the voting must be documented and disclosed [26] Chapter 6: Meeting Records - Detailed records of board meetings must be maintained, including attendance and decisions made [28][29] Chapter 7: Supplementary Provisions - These rules serve as a supplement to the company's articles of association and must comply with national laws [31][32]

第四条 公司聘用或解聘会计师事务所，由审计委员会审议同意后，提交董 事会审议，并由股东会决定。董事会不得在股东会决定前委任会计师事务所开展 工作。 亿帆医药股份有限公司 YIFAN PHARMACEUTICAL CO.,LTD. 会计师事务所选聘制度 （二 O 二五年八月修订） 第一章 总则 第一条 为提高财务信息质量，维护股东权益，规范亿帆医药股份有限公司 （以下简称"公司"）选聘对公司进行审计的会计师事务所的行为， 根据《中华 人民共和国公司法》（以下简称" 《公司法》 "）、《中华人民共和国证券法》 （以下简称"《证券法》"）、《国有企业、上市公司选聘会计师事务所管理办法》 《深圳证券交易所股票上市规则》等相关法律法规和规范性文件， 以及《公司 章程》的相关规定，结合实际情况，制定公司会计师事务所选聘制度。 第二条 本制度描述的会计师事务所，是指根据中国证券监督管理委员会 （"中国证监会"）、证券交易所的要求，对公司财务报告、内部控制报告及相关 信息进行审计的会计师事务所。 公司在聘请会计师事务所进行年度审计的同时，应当要求会计师事务所对财 务报告内部控制的有效性进行审计并出具审计报告，法律法规另有规定 ...

投资管理制度 亿帆医药股份有限公司 YIFAN PHARMACEUTICAL CO.,LTD. 投资管理制度 （二 O 二五年八月修订） 投资管理制度 目 录 第一章 总 则 第一条 为规范亿帆医药股份有限公司（以下简称"本公司"或"公司"）投 资决策及实施，完善公司法人治理结构，充分维护公司及股东利益，依据《中华 人民共和国公司法》 《中华人民共和国证券法》 《上市公司信息披露管理办法》 《深 圳证券交易所股票上市规则》《上市公司自律监管指引第 1 号—主板上市公司规 范运作》等相关法律法规、规范性文件和《亿帆医药股份有限公司章程》（以下 简称"《公司章程》"）的有关规定，特制定本制度。 第二条 本制度述及的投资是指公司以现金、实物、无形资产或购买股票、 债券等有价方式向其他单位、子（分）公司及公司自身建设的投资，法律形式上 包括但不限于出资设立其他经营实体、受让股权、认购债券等。 第三条 公司以固定资产、无形资产等非货币投资的，应按有关法律、法规 办理相应过户手续。 第四条 公司净资产值的确定以公司最近一期经审计的财务报告并参照公司 动态财务资料得出。 第二章 投资的决策权限 第五条 投资事务原则上应由董 ...

目 录 信息披露事务管理制度 第一章 总则 第一条 为规范亿帆医药股份有限公司（以下简称"本公司"或"公司"）及其 他信息披露义务人的信息披露行为，加强信息披露事务管理，保护投资者合法权益， 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司信息披露管 理办法》《深圳证券交易所股票上市规则》（以下简称"《上市规则》"）等相关 法律、法规、规范性文件和《亿帆医药股份有限公司章程》（以下简称"《公司章 程》"）的有关规定，特制定本制度。 第二条 信息披露义务人应当及时依法履行信息披露义务，披露的信息应当真实、 准确、完整，简明清晰、通俗易懂，不得有虚假记载、误导性陈述或重大遗漏。 信息披露事务管理制度 （二 O 二五年八月修订） 亿帆医药股份有限公司 YIFAN PHARMACEUTICAL CO.,LTD. 信息披露事务管理制度 信息披露事务管理制度 公司披露的信息应当同时向所有投资者披露，不得提前向任何单位和个人泄露。 但是，法律、行政法规另有规定的除外。 在内幕信息依法披露前，内幕信息的知情人和非法获取内幕信息的人不得公开 或者泄露该信息，不得利用该信息进行内幕交易。任何单位和个人不得非法要求信 ...

Core Points - The company is Yifan Pharmaceutical Co., Ltd., established as a joint-stock company in accordance with Chinese laws [1][2] - The registered capital of the company is RMB 1,216,390,085 [2] - The company was approved for its initial public offering of 15 million shares in 2004 and is listed on the Shenzhen Stock Exchange [1][3] Company Structure - The company is governed by a board of directors, with the legal representative being elected from among the directors [2] - The company has a permanent existence as a joint-stock company [2] - Shareholders are liable for the company's debts only to the extent of their subscribed shares [2] Business Objectives and Scope - The company's mission is to promote health and happiness through innovation and rigorous management [3] - The business scope includes research and sales of food additives, feed additives, pharmaceutical intermediates, and biotechnology [3] Share Issuance and Management - The company issues shares in the form of stocks, with each share having a face value of RMB 1 [5] - The total number of shares issued by the company is 1,216,390,085 [5][6] - The company cannot provide financial assistance for others to acquire its shares, except under specific conditions [6] Shareholder Rights and Responsibilities - Shareholders have rights to dividends, voting, and supervision of company operations [11] - Shareholders holding more than 3% of shares for over 180 days can access the company's accounting records [12] - Shareholders must comply with laws and the company's articles of association, and they are liable for damages caused by abuse of rights [17] Governance and Decision-Making - The company holds annual and extraordinary shareholder meetings to make key decisions [48][49] - Decisions require a majority or two-thirds majority vote depending on the nature of the resolution [80][82] - The board of directors is responsible for convening shareholder meetings and ensuring compliance with legal requirements [52][53]